Breast Cancer Index Identifies Women Likely to Benefit From Extended Hormone Therapy, Latest Data Show

Breast Cancer Index Identifies Women Likely to Benefit From Extended Hormone Therapy, Latest Data Show
The Breast Cancer Index, a molecular test developed by Biotheranostics, successfully identified a group of women with hormone receptor (HR)-positive breast cancer who may benefit from long-term hormone therapy with tamoxifen, data from a Phase 3 trial shows. Study findings were presented in a poster, titled "Breast Cancer Index predicts benefit from extended endocrine therapy in HR+ breast cancer," at the 42nd Annual San Antonio Breast Cancer Symposium, in San Antonio, Texas. Anti-estrogen therapies, such as tamoxifen, are a form of endocrine therapy that works by depriving cancer cells of the hormones, mainly estrogen, that promote their growth. For women with HR-positive breast cancer, these therapies can be lifesaving. However, hormone therapy can also cause a series of unpleasant side effects, including osteoporosis, joint pain, blood clots, and endometrial cancer. For that reason, determining the best timing of treatment for each patient is important to ensure the maximum benefits and avoid undesirable side effects. "Current clinical practice guidelines recommend 10 years of adjuvant endocrine therapy for most patients unless there are characteristics of low risk disease. However, approximately [two-thirds] of patients have favorable long-term outcomes after completing 5 years of adjuvant therapy," the investigators said. "Therefore, consideration of the risk-benefit profile for each patient is critical to identify who may be spared extended endocrine therapy and its associated toxicities, and which patients will benefit from an additional 5 years of endocrine therapy," they added. In an attempt to solve this problem, Biotheranostics created the Breast Cancer Index (BCI), a molecular test that is able to tell which genes are active inside tumors,
Subscribe or to access all post and page content.